Vaxcyte insider surrenders 1,327 shares for tax

Vaxcyte’s finance chief surrendered shares to cover RSU tax withholding, leaving a direct holding of 27,860 common shares.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reported that Elvia Cowan, its Senior Vice President, Finance and Chief Accounting Officer, surrendered 1,327 shares of common stock on September 8, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were valued at $60.36 per share for this purpose, and Cowan now holds 27,860 shares of Vaxcyte common stock directly. This was a tax-withholding share disposition, not an open-market sale, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Tax Withholding: 1,327 shares

Tax Withholding 1 txn

Insider Cowan Elvia

Role SVP, Finance & CAO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	1,327	$60.36	$80K

Holdings After Transaction: Common Stock — 27,860 shares (Direct)

Footnotes (1)

1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Key Figures

Shares surrendered for tax withholding: 1,327 shares Share valuation for tax withholding: $60.36 per share Direct holdings after transaction: 27,860 shares

3 metrics

Shares surrendered for tax withholding 1,327 shares Common stock surrendered on September 8, 2026 to cover RSU tax withholding

Share valuation for tax withholding $60.36 per share Value used for the 1,327 surrendered shares on September 8, 2026

Direct holdings after transaction 27,860 shares Common shares directly held by Elvia Cowan following the September 8, 2026 surrender

Key Terms

restricted stock units, tax withholding obligations, surrendered to the Issuer

3 terms

restricted stock units financial

"realized upon the vesting of RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to cover applicable tax withholding obligations realized upon the vesting"

surrendered to the Issuer financial

"Represents shares surrendered to the Issuer to cover applicable tax"

FAQ

What insider transaction did Vaxcyte (PCVX) disclose for Elvia Cowan?

Vaxcyte disclosed that Elvia Cowan surrendered 1,327 shares of common stock on September 8, 2026 to the company to cover tax withholding obligations triggered by vesting restricted stock units.

Was the Vaxcyte (PCVX) insider transaction an open-market sale?

No. The filing states the 1,327 shares were “surrendered to the Issuer to cover applicable tax withholding obligations” upon RSU vesting, indicating a tax-withholding disposition rather than an open-market sale.

At what price were the surrendered Vaxcyte (PCVX) shares valued?

The 1,327 surrendered shares were valued at $60.36 per share for the tax-withholding transaction reported on September 8, 2026.

How many Vaxcyte (PCVX) shares does Elvia Cowan hold after the reported transaction?

After the tax-withholding share surrender, Elvia Cowan directly holds 27,860 shares of Vaxcyte common stock, according to the Form 4 filing.

Was a Rule 10b5-1 trading plan involved in this Vaxcyte (PCVX) Form 4?

No. The Form 4 indicates that the transaction was not made under a Rule 10b5-1 trading plan; it was a share surrender to satisfy RSU-related tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:52 PM Accepted by SEC EDGAR 09/09/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		F		1,327(1)	D	$60.36	27,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)